Equities research analysts expect Intrexon Corp (NASDAQ:XON) to announce $32.16 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Intrexon’s earnings, with the highest sales estimate coming in at $32.80 million and the lowest estimate coming in at $31.51 million. Intrexon reported sales of $32.45 million during the same quarter last year, which indicates a negative year-over-year growth rate of 0.9%. The company is scheduled to announce its next earnings results on Thursday, November 14th.
According to Zacks, analysts expect that Intrexon will report full year sales of $124.66 million for the current financial year, with estimates ranging from $122.21 million to $127.10 million. For the next fiscal year, analysts anticipate that the business will report sales of $64.51 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Intrexon.
Intrexon (NASDAQ:XON) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.05. The company had revenue of $35.99 million for the quarter, compared to the consensus estimate of $29.62 million. Intrexon had a negative net margin of 368.47% and a negative return on equity of 31.89%. Intrexon’s revenue for the quarter was down 20.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.51) EPS.
In other Intrexon news, CEO Randal J. Kirk purchased 203,321 shares of the stock in a transaction dated Tuesday, June 4th. The stock was purchased at an average price of $4.91 per share, with a total value of $998,306.11. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Randal J. Kirk purchased 330,180 shares of the stock in a transaction dated Thursday, May 30th. The stock was acquired at an average cost of $4.75 per share, with a total value of $1,568,355.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 1,016,769 shares of company stock worth $5,098,985 and have sold 22,672 shares worth $173,474. Corporate insiders own 44.00% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. PFG Advisors increased its stake in Intrexon by 21.7% during the 2nd quarter. PFG Advisors now owns 12,350 shares of the biotechnology company’s stock valued at $94,000 after purchasing an additional 2,200 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in Intrexon by 4.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 58,956 shares of the biotechnology company’s stock valued at $452,000 after purchasing an additional 2,600 shares in the last quarter. LPL Financial LLC increased its stake in Intrexon by 15.8% during the 2nd quarter. LPL Financial LLC now owns 19,494 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 2,659 shares in the last quarter. First Republic Investment Management Inc. increased its stake in Intrexon by 13.9% during the 2nd quarter. First Republic Investment Management Inc. now owns 41,000 shares of the biotechnology company’s stock valued at $314,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Intrexon by 1.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 417,274 shares of the biotechnology company’s stock valued at $3,197,000 after purchasing an additional 5,612 shares in the last quarter. 75.49% of the stock is owned by hedge funds and other institutional investors.
NASDAQ XON traded down $0.26 on Tuesday, reaching $5.60. The company had a trading volume of 46,099 shares, compared to its average volume of 1,358,696. The stock’s 50 day moving average is $7.24. Intrexon has a 12 month low of $3.95 and a 12 month high of $19.94. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.55 and a quick ratio of 3.20. The stock has a market cap of $949.73 million, a PE ratio of -4.08 and a beta of 2.22.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Read More: What is the LIBOR?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.